ABC Heart Fail Cardiomyop 2022; 2(3): 299-303
Flowchart for Treatment of Heart Failure with Preserved Ejection Fraction
Viviane Melo e Silva de Figueiredo
, João Vitor Soares Santos
, Natália Garcia Galvão
, José Albuquerque de Figueiredo Neto
Abstract
Heart failure with preserved ejection fraction (HFpEF) manifests as a heterogeneous syndrome, with pathophysiological variety, often associated with other comorbidities. Furthermore, the therapy performed in these patients is related to the treatment of correlated comorbidities. In this context, the specific pharmacological treatment of HFpEF is a challenge, given the lack of evidence from studies that would prove a significant reduction in mortality outcomes. In this article, we will analyze the management for the control of arterial hypertension and atrial fibrillation as well as evidence from studies on the use of the main classes of medications recommended for the treatment of patients with HFpEF, such as sodium-glucose cotransporter 2 inhibitors, renin-angiotensin system inhibitors, neprilysin inhibitors, and nitrates.
7,880
